US 11,883,440 B2
Nanovesicle derived from Proteus genus bacteria, and use thereof
Yoon-Keun Kim, Paju-si (KR)
Assigned to MD HEALTHCARE INC., Seoul (KR)
Filed by MD HEALTHCARE INC., Seoul (KR)
Filed on Feb. 15, 2021, as Appl. No. 17/175,925.
Application 17/175,925 is a continuation of application No. 16/362,176, filed on Mar. 22, 2019, granted, now 11,040,074.
Application 16/362,176 is a continuation of application No. PCT/KR2018/007144, filed on Jun. 25, 2018.
Claims priority of application No. 10-2017-0083047 (KR), filed on Jun. 30, 2017; and application No. 10-2018-0072307 (KR), filed on Jun. 22, 2018.
Prior Publication US 2021/0169944 A1, Jun. 10, 2021
Int. Cl. A61K 35/74 (2015.01); A61K 9/00 (2006.01); C12Q 1/689 (2018.01); A61P 25/28 (2006.01); A61K 9/127 (2006.01); A61P 35/00 (2006.01); A61P 29/00 (2006.01); C12Q 1/6886 (2018.01); A61K 39/00 (2006.01); A61K 38/00 (2006.01)
CPC A61K 35/74 (2013.01) [A61K 9/0053 (2013.01); A61K 9/0073 (2013.01); A61K 9/127 (2013.01); A61P 25/28 (2018.01); A61P 29/00 (2018.01); A61P 35/00 (2018.01); C12Q 1/689 (2013.01); C12Q 1/6886 (2013.01); A61K 38/00 (2013.01); A61K 39/00 (2013.01); A61K 2039/6037 (2013.01)] 6 Claims
 
1. A method of reducing inflammation mediated by TNF-α or IL-6, comprising administering a composition comprising an effective amount of vesicles isolated from bacteria belonging to Proteus mirabilis to the subject having the inflammation.